The antitumor peptide CIGB-552 demonstrated significant tumor growth inhibition in mouse models, with an optimized IV formulation showing superior pharmacokinetics and efficacy over other routes.
IV route optimalIntravenous delivery provided the best blood levels and tumor exposure for the antitumor peptide CIGB-552
What the researchers found
CIGB-552 demonstrated significant antitumor activity in vivo, with IV administration providing optimal pharmacokinetics and superior efficacy over other routes, supported by acceptable safety profiling.
Why it matters
Developing peptide-based cancer drugs requires careful formulation and route optimization. CIGB-552 advances as a viable antitumor peptide with clinical development potential.
How the study worked
Formulation optimization, multi-route pharmacokinetic comparison (IV, SC, other), in vivo antitumor efficacy in mouse tumor models, and toxicology assessment.
What this study cannot tell us
Mouse tumor models. Specific mechanism of action not fully detailed in this study. Clinical translation pathway uncertain.
How to read the evidence
Preclinical study with formulation optimization and in vivo efficacy. Advancing toward clinical development.
When this study was published
Published in 2025.
The bigger picture
CIGB-552 represents peptide-based oncology from Cuba, demonstrating that innovative cancer therapeutics emerge from diverse global research communities.
Questions still open
- What is CIGB-552's specific mechanism of antitumor action?
- How does it compare to existing peptide cancer drugs?
- Is clinical trial enrollment underway?
Common questions
What is CIGB-552?
Is this available for patients?
Read the original research
In vivo evaluation of the antitumor peptide CIGB-552: antitumor activity, pharmacokinetics and safety of the subcutaneously administered peptide.
Cancer chemotherapy and pharmacology, 96(1)
Citation
Gómez Hernández, Nivaldo Angel; Martínez Durán, Luis Miguel; Milian, Héctor Santana; Garay Pérez, Hilda Elisa; Etchegoyen Amoros, Ana Yanci; Arguellez, Brizaida Oliva; Velazco, Lizet Aldana; Velazco, Jorge Castro; Rico, Ania Cabrales; Lemos, Mariana Machado; Fernández Massó, Julio Raúl. (2026). In vivo evaluation of the antitumor peptide CIGB-552: antitumor activity, pharmacokinetics and safety of the subcutaneously administered peptide.. Cancer chemotherapy and pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04867-z